Matinas Biopharma Holdings, Inc. · AMEX:MTNB
Matinas Biopharma — Investor Presentation (May 2018)
29 slides from Matinas Biopharma's investor presentation, May 25, 2018
Slide 1: Corporate Presentation May 2018
NYSE AMERICAN: MTN WWW.MATINASBIOPHAR MATINAS ~ BIOPHARMA Enabling the Delivery of Life-Changing Medicines Corporate Presentation c. May 2018 S: *)
Slide 2: Forward-Looking Statements
Forward —L This presentation contains “forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's expectations regarding the terms and size of the proposed offering and the use of proceeds from the proposed offeri
Slide 3: Offering Summary
Offering Summary Issuer Matinas BioPharma Holdings, Inc. Exchange / Symbol NYSE American / MTNB Expected Offering Size $15,000,000 Securities Offered Series B Convertible Preferred Shares Development of MAT2203 and general Use of Proceeds corporate purposes ThinkEquity, a division of Fordham Financi
Slide 4: Series B Convertible Preferred Shares Summary
Series B Convertible Pr ares”) Summa Offering Price / Stated Value per Share | $1,000.00 $0.50 (each Share is convertible into 2,000 shares of Common Stock) Conversion Price At any time at the option of the holder * Automatic conversion upon the earlier of (i) the first FDA approval of one of the Co
Slide 5: Strategy Overview
ategy Overview Enabling Delivery of Life-Changing Medicines Using a Proprietary Lipid Nano-Crystal (LNC) Technology Platform LNC Technology Platform * Highly stable lipid crystals enable safe and natural intracellular delivery of: — siRNAs, mRNA, proteins, small molecule pharmaceuticals and the pote
Slide 6: LNC Platform Technology Enables Safe and Targeted Delivery
LNC Platform Technology Enables Safe and Targeted Delive Potent Medicines Highly stable lipid crystal particles Lipid Nano-Crystal vs. Lipid Nano-Particle Lipid Nano-Crystal Sheets roll up and capture drug molecules . between the sheet Validated in multiple clinical and preclinical LNG studies Multi
Slide 7: LNC cellular delivery mechanism
* Naturally targeted to cells of the immune system (e.g. a macrophage, dendritic cells, neutrophils) or virally . / 2) infected cells Pe, ° Enter cells through non-destructive, natural membrane fusion Lipté Nano-Crystals a X me ° Naturally unwind (low calcium environment) releasing 1 | af \s Ghopies
Slide 8: MAT2203: Lead Development Product Candidate
MAT2203: Lead Development Product Candidate Proof of Concept for LNC Technology Platform MATINAS
Slide 9: MAT2203: C-Amphotericin B (CAmB)
MAT2203: C-Amphotericin B (CAmB) QIDP with Fast Track Status for Treatment of Aspergillus, Invasive Candidiasis and Prevention of IFI Demonstrated to be Safe and Well Tolerated Broadest Spectrum Antifungal Agent LNC Platform Technology Benefits KY Gold standard of treatment for immunocompromised pat
Slide 10: Invasive fungal infection burden and cost
Limited population annually in US: Treatment period limited: Significant morbidity and mortality lat a rate in patients with IFI; mortality risk 40%-90%, depending on fungal species Significant cost of treatment for IF1, adding ~$50 000 per IFI case in 2016 dollars 10
Slide 11: NIH and VVC Studies Strengthen MAT2203 Human Safety and PK Database
NIH and VVC Studies Significantly Strengthen MAT2203 Human Safety and PK Database Current Database: Safety 24-hr PK in Serum Other PK Single Dose 36 patients 36 patients none Multiple Dose 96° patients 21 patients 70° patients ® NIH Study: Kidney and liver function remained within normal ranges * Vu
Slide 12: Efficacy Results — NIH and VVC Phase 2 Studies
Efficacy Results — NIH and VVC Phase 2 Studies NIH Study * 100% (4 out of 4) patients met the primary endpoint in achieving > 50% clinical response * Study met predetermined endpoint for success, which was 3/16 patients demonstrating clinical response * All patients reported improved quality of life
Slide 13: Recent Meeting with FDA Provided Clarity on Clinical Development Path
Recent Meeting with FDA Provided Clarity on Clinical Development Path Forward ° FDA meeting held in January 2018 with purpose of gaining FDA perspectives on data from studies conducted and on future development of MAT2203 ° FDA acknowledged efficacy was demonstrated in animal studies ° FDA acknowled
Slide 14: MAT2203 Formulation Optimization
MAT2203 Formulation Optimization ° Current formulation is an oral suspension ° Recently completed formulation optimization program with a goal to reduce product volume and improve taste — Reformulation through concentration (improved from 5 mg/mL to 27.5 mg/mL) — Taste-masked, sweetened, flavored an
Slide 15: MAT2203 Dose Optimization Through Animal Studies & PK/PD Modeling
MAT2203 Dose Optimization Through Animal Studies & Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling Robust Studies in Neutropenic Animals Stage 1 * Designed to provide data for input into the PK/PD Model PK/PD Modeling with Existing Data Stage 2 e Will run concurrently with Stage 1 * Population phar
Slide 16: Single Phase Pivotal - Adaptive Design Study
Single Phase 2 Pivotal - Adaptive Design Study Seeking Approval for Limited Use Indication for Prevention of IFI in ALL Patients Stage 2: PK/PD, Efficacy and Safety in ALL Patients : * Final number of patients for Stage 2 to be determine: Stage 1 Final number of for Stage 2 to be d d PK/PD and Safet
Slide 17: MAT2203 Clinical Development
MAT2203 Clinical Developme Dose Optimization Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling Long Term Tox (90 Rat & Dog) and Food Effect Studies P| FDA Meeting XN ™ Initiate Phase 2 Pivotal - Adaptive Design Study S is Phase 2 Pivotal Study Duration NDA MATINAS Prorna 17
Slide 18: LNC Platform Delivery Technology — The Future
LNC Platform Delivery Technology — The Future Enabling the Promise of Gene Therapy/Editing MATINAS
Slide 19: The Challenge of Delivery in Gene Therapy/Editing
The Challenge of Delivery in Gene Therapy/Editing Genetic drugs such as small interfering RNA (siRNA), messenger RNA (mRNA) or plasmid DNA provide potential gene therapies to treat most diseases by silencing pathological genes, expressing therapeutic proteins, or through gene-editing applications. I
Slide 20: The LNC Platform Technology: A Demonstrated Gene Therapy Solution
The LNC Platform Technology: A Demonstrated Gene Therapy Solution Encapsulation of genetic information — LNCs protect associated genetic information inside stable, solid crystal Attachment and delivery into target cells — Natural membrane fusion intermediates due to inherent physical/chemical proper
Slide 21: How LNCs Deliver RNA and DNA Polymers
How LNCs Deliver RNA and DNA Polymers see —— ssp ett —— epee ty Cell Interior = we Sg The outer layer of the LNC interacts Via a natural, non-destructive membrane fusion with the target cell membrane process, involving calcium and negatively charged phospholipids, the LNC membrane fuses with the tar
Slide 22: Preclinical Data Support Formulation and Delivery of RNA and DNA Polymers
Preclinical Data Support Formulation and Delivery of RNA and DNA Polymers * Various strategies have been developed to prepare stable formulations of siRNA, mRNA and DNA plasmids ° Greater than 90% efficiency and demonstrated long shelf life stability (including at room temperature) * Formulations de
Slide 23: Intracellular Localization of siRNA in RISC Complexes
Intracellular Localization of siRNA in RISC Complexes Light Micros Fluorescence Microscopy * LNCs deliver siRNA at high efficiency to every cell in the culture * Fluorescent siRNA localizes regions in the cytoplasm next to the nuclear membrane analogous to RISC complexes 23
Slide 24: Pipeline Through Strategic Collaboration — Formulation Partner of Choice
Pipeline Throu ategic Collaboration— Formulation Partner of Choice r LNC Platform Benefits Broad Applicability * Demonstrated oral, parenteral and topical Unique delivery platform that can formulate and delivery stabilize a variety of molecules: * Demonstrated intracellular delivery of drug siRNAs *
Slide 25: Manufacturing Capabilities
Manufacturing Capabilities © 14,000+ sq. ft. GLP/GMP product development and manufacturing facility located in former Sanofi R&D building in Bridgewater, NJ ° Includes GMP scale-up and manufacturing suites ISO-8 compliant ° Highly scalable and reproducible manufacturing process from 1 mL to 100 lite
Slide 26: Management Team and Board of Directors
Management Team and Board of Directors Strong Development and Commercialization Track Record Management Board of Directors Jerome D. Jabbour Herbert Conrad gt. Chief Executive Officer, Director CG Reliant TWOCKHARDT Chairman of the Board PHARMASSET Raphael J. Mannino, PhD RuTc i : ™~ Eric J. Ende, M
Slide 27: Prominent Clinical Advisors
Prominent Clinical Advisors J. Carl Craft, MD - Chair + Former Chief Scientific Officer for Medicines for Malaria Venture (MMV) MMV @@0: co) Abbott + Former Venture Head at Abbott Laboratories Anti-Infective Development Group Medicines for Malaria Venture Prof. Oliver Cornely, MD, FACP, FIDSA ° + He
Slide 28: Capitalization Table
Capitalization Table” Common Shares 93,981,562 Series A Preferred Stock (as converted)** 14,728,858 Options ($1.33 WAEP) 11,613,820 Warrants ($0.70 WAEP) 5,957,831 * Pre-offering and excluding: the Series B Convertible Preferred Shares and Common Shares into which the Shares convert; 3,000,000 Commo
Slide 29: NYSE American: MTNB
NYSE AMERICAN; MTNB “MATINAS ° BIOPHARMA Enabling the Delivery of Life-Changing Medicines
Matinas BioPharma Holdings — Investor Presentation (May 2018) on 6ix